HOMEVULNERABILITIESCVE-2004-2030
MEDIUMPOC

CVE-2004-2030

CWE-79Published: May 22, 2004· Updated: Jun 16, 2026

4.3
CVSS v3.1

Official Description

Multiple cross-site scripting (XSS) vulnerabilities in index.jsp for Liferay before 2.2.0 release 10/1/2004 allow remote attackers to inject arbitrary web script or HTML, as demonstrated using the message subject.

NVD Source

Technical Analysis

CVE-2004-2030 can be exploited remotely over the network without requiring physical or adjacent access, significantly expanding the attack surface for threat actors.

Exploitation requires some privileges, which limits the exposure to scenarios where an attacker has already gained initial access.

A proof-of-concept (PoC) exploit exists for CVE-2004-2030. While not yet confirmed in active campaigns, the availability of PoC code increases exploitation risk substantially.

From a weakness classification perspective (CWE-79): Cross-site scripting (XSS) vulnerabilities allow attackers to inject malicious scripts into web pages viewed by other users.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorNetwork
Attack ComplexityM
Privileges Req.
User Interaction
Scope
Impact
ConfidentialityNone
IntegrityP
AvailabilityNone
AV:N/AC:M/Au:N/C:N/I:P/A:N

Affected Vendors & Products

liferay1 product(s)
liferay enterprise portal
Source: NVD CPE · 2 total CPE entries

Exploit & PoC Resources

POC AVAILABLEProof-of-concept code exists
External links open in a new tab. Always verify in a controlled environment before use.

Official Patches & Advisories

All References (16)

Quick Facts

CVE IDCVE-2004-2030
CVSS Score4.3 / 10
SeverityMEDIUM
WeaknessCWE-79
CISA KEVNo
ExploitPOC
Affected1 vendor(s)
PublishedMay 22, 2004

Related CVEs (CWE-79)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2004-2030 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.